Key result
Targeted therapies for hematologic malignancies drive distinct CV toxicities requiring personalized cardio-oncology management.
Why the study?
Targeted therapies for hematologic malignancies cause distinct cardiotoxicities, but clinical management is limited by lacking standardized adverse event reporting and complex risk stratification tools.
Highlights the need for personalized cardiovascular surveillance and multidisciplinary cardio-oncology teams to manage cardiotoxicity from targeted therapies in hematologic malignancies without prematurely discontinuing oncologic treatment.
No takes yet. Share an insight, caveat, or question.
Personalized monitoring may mitigate cardiotoxicity during targeted therapy; leaves open optimal protocols and long-term outcomes.
Lin et al. (2026) conducted a review in Hematologic malignancies. Targeted therapies was evaluated. Targeted therapies for hematologic malignancies cause distinct cardiovascular toxicities, requiring personalized surveillance and multidisciplinary cardio-oncology management.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: